Brokerages Expect Citius Pharmaceuticals Inc (NASDAQ:CTXR) to Post ($0.06) EPS

Citius Pharmaceuticals Inc (NASDAQ:CTXR) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Zacks has also given Citius Pharmaceuticals an industry rank of 85 out of 256 based on the ratings given to its competitors.

A hedge fund recently raised its stake in Citius Pharmaceuticals stock. Vanguard Group Inc. boosted its position in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 453,156 shares of the company’s stock after buying an additional 342,180 shares during the period. Vanguard Group Inc. owned approximately 2.05% of Citius Pharmaceuticals worth $444,000 at the end of the most recent quarter. 1.47% of the stock is currently owned by institutional investors.



NASDAQ:CTXR traded up $0.01 during midday trading on Wednesday, hitting $1.08. The company had a trading volume of 9,900 shares, compared to its average volume of 153,525. Citius Pharmaceuticals has a 52-week low of $0.86 and a 52-week high of $2.52. The stock’s fifty day moving average price is $1.11 and its 200-day moving average price is $1.15. The company has a market capitalization of $23.85 million, a PE ratio of -0.92 and a beta of 0.55.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

See Also: What are convertible shares? 

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.